Efficacy of Adaptogens in Patients With Long COVID-19

Inclusion Criteria: * COVID-19 patients with confirmed diagnosis based on positive SARS-Cov-2 test and the symptom of at least three of Long COVID-19 symptoms including: fatigue, headache, respiration problems (dyspnea or polypnea), sweat, cognitive disorders (attention, memory, anxiety and depression), loss of smell (anosmia) and taste (ageusia), cough, pain in joints. muscles and chest. * Post COVID-19 patients discharged from Covid Hotels isolation, after hospitals and Intensive Care Unit (ICU) admission. * Subjects must be under observation or admitted to a controlled facility or hospital (home quarantine is not sufficient). * Able to take medication alone. * Able to give informed consent. Exclusion Criteria: * Post COVID-19 patients discharged from Covid Hotels isolation, after hospitals and Intensive Care Unit (ICU) admission and Long Covid Symptoms longer that 3 months. * Patient admitted already under invasive mechanical ventilation; * Patient admitted with severe acute respiratory syndrome and diagnosed with an etiologic agent other than SARS-CoV-2; * Renal failure requiring dialysis or creatinine ≥ 2.0mg/dl; * Tube feeding or parenteral nutrition. * Respiratory decompensation requiring mechanical ventilation. * Uncontrolled diabetes type 2. * Autoimmune disease. * Pregnant or lactating women. * Taking antibiotics for a reason other than COVID-19 at enrollment; * Has a chronically weakened immune system (AIDS, lymphoma, chemo-radio- corticosteroid therapy, immunosuppressive pathology); * Was treated with chemo-radio-corticosteroid therapy in the last 6 months; * Has active cancer; * Taking immunosuppressive drugs (e.g. anti-rejection treatment after organ transplant); * Already participating in another clinical trial; * Has any other condition that would prevent safe participation in the study.